Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study / Xueliang PAN ; Taylor WONG ; Craig WILLIAMS ; Cheryl JAMES ; L. Eugene ARNOLD in Research in Autism, 125 (July 2025)  

Public ISBD [article]  inResearch in Autism > 125 (July 2025) . - p.202603 Titre : Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study Type de document : texte imprimé Auteurs : Xueliang PAN, Auteur ; Taylor WONG, Auteur ; Craig WILLIAMS, Auteur ; Cheryl JAMES, Auteur ; L. Eugene ARNOLD, Auteur Article en page(s) : p.202603 Langues : Anglais (eng) Mots-clés : Essential oils  Autism spectrum disorder  Feasibility study  Quality of life  Sleep  Anxiety  Proinflammatory cytokines Index. décimale : PER Périodiques Résumé : Introduction Essential oils have been touted to benefit children with autism spectrum disorder (ASD) in a multitude of ways. However, the lack of empirical evidence makes it difficult to accept this claim. We tested the feasibility of conducting a large randomized clinical crossover trial of an essential oils blend in children with ASD and evaluated its safety and efficacy for improving quality of life. Methods Children ages 3-9 with ASD were randomized to a crossover study of Reconnect?, an essential oils blend, versus a control. Outcomes were the Pediatric Quality of Life Inventory, Parent-Rated Anxiety Scale for ASD, Children s Sleep Habits Questionnaire, and laboratory safety tests. Inflammatory cytokines and other labs were explored. Mixed-effects analyses were applied. Results Twenty-six participants evaluated as intent-to-treat population. Seventeen completed both conditions (61 %). Outcomes improved, but between-treatment differences in the crossover were nonsignificant (p = .33-.16). At first treatment endpoint, anxiety decreased significantly more with active than control (p = .015, d=1.01). Adverse events and hematological/hepatic/renal tests revealed no significant differences. C-reactive protein and interleukin-6 (IL-6) revealed no inflammation. Conclusion Recruitment was feasible, adherence was high, first-condition retention was high (92.7 %). Retention in second condition was low (65.4 %). A large crossover is not feasible. Anxiety results suggest further study in a randomized controlled trial with a parallel-groups design. Reconnect? appears safe. En ligne : https://doi.org/10.1016/j.reia.2025.202603 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=559 [article] Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study [texte imprimé] / Xueliang PAN, Auteur ; Taylor WONG, Auteur ; Craig WILLIAMS, Auteur ; Cheryl JAMES, Auteur ; L. Eugene ARNOLD, Auteur . - p.202603. Langues : Anglais (eng) in Research in Autism > 125 (July 2025) . - p.202603 Mots-clés : Essential oils  Autism spectrum disorder  Feasibility study  Quality of life  Sleep  Anxiety  Proinflammatory cytokines Index. décimale : PER Périodiques Résumé : Introduction Essential oils have been touted to benefit children with autism spectrum disorder (ASD) in a multitude of ways. However, the lack of empirical evidence makes it difficult to accept this claim. We tested the feasibility of conducting a large randomized clinical crossover trial of an essential oils blend in children with ASD and evaluated its safety and efficacy for improving quality of life. Methods Children ages 3-9 with ASD were randomized to a crossover study of Reconnect?, an essential oils blend, versus a control. Outcomes were the Pediatric Quality of Life Inventory, Parent-Rated Anxiety Scale for ASD, Children s Sleep Habits Questionnaire, and laboratory safety tests. Inflammatory cytokines and other labs were explored. Mixed-effects analyses were applied. Results Twenty-six participants evaluated as intent-to-treat population. Seventeen completed both conditions (61 %). Outcomes improved, but between-treatment differences in the crossover were nonsignificant (p = .33-.16). At first treatment endpoint, anxiety decreased significantly more with active than control (p = .015, d=1.01). Adverse events and hematological/hepatic/renal tests revealed no significant differences. C-reactive protein and interleukin-6 (IL-6) revealed no inflammation. Conclusion Recruitment was feasible, adherence was high, first-condition retention was high (92.7 %). Retention in second condition was low (65.4 %). A large crossover is not feasible. Anxiety results suggest further study in a randomized controlled trial with a parallel-groups design. Reconnect? appears safe. En ligne : https://doi.org/10.1016/j.reia.2025.202603 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=559

A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges / Laura SILVERMAN in Research in Autism Spectrum Disorders, 8-7 (July 2014)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 8-7 (July 2014) . - p.899-907 Titre : A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges Type de document : texte imprimé Auteurs : Laura SILVERMAN, Auteur ; Jill HOLLWAY, Auteur ; Tristram SMITH, Auteur ; Michael G. AMAN, Auteur ; L. Eugene ARNOLD, Auteur ; Xueliang PAN, Auteur ; Xiaobai LI, Auteur ; Benjamin L. HANDEN, Auteur Article en page(s) : p.899-907 Langues : Anglais (eng) Mots-clés : Atomoxetine (Strattera)  ADHD  Autism spectrum disorder  Drug trial  Parent training Index. décimale : PER Périodiques Résumé : Abstract Several randomized controlled trials (RCTs) involving children with autism spectrum disorder (ASD) have examined effectiveness of mono-therapies for problem behavior. However, results have not been as encouraging as in typically developing children. For example, when prescribed stimulants, children with ASD and hyperactivity/inattentiveness, show only moderately reduced symptoms, with frequent side effects. Therefore, alternative treatments or combinations of treatments are needed. The Children's Hyperactivity and Autism Research Treatment Study (CHARTS) is a randomized clinical trial comparing the individual and combined effects of atomoxetine and parent training to treat hyperactivity, inattentiveness, and noncompliance in children with ASD. Design challenges included the overall study design, targeting of different outcomes by different treatments, and data analysis. This article details options for addressing a number of these methodological issues in the context of conducting a large multicenter RCT with an ASD population. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233 [article] A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges [texte imprimé] / Laura SILVERMAN, Auteur ; Jill HOLLWAY, Auteur ; Tristram SMITH, Auteur ; Michael G. AMAN, Auteur ; L. Eugene ARNOLD, Auteur ; Xueliang PAN, Auteur ; Xiaobai LI, Auteur ; Benjamin L. HANDEN, Auteur . - p.899-907. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 8-7 (July 2014) . - p.899-907 Mots-clés : Atomoxetine (Strattera)  ADHD  Autism spectrum disorder  Drug trial  Parent training Index. décimale : PER Périodiques Résumé : Abstract Several randomized controlled trials (RCTs) involving children with autism spectrum disorder (ASD) have examined effectiveness of mono-therapies for problem behavior. However, results have not been as encouraging as in typically developing children. For example, when prescribed stimulants, children with ASD and hyperactivity/inattentiveness, show only moderately reduced symptoms, with frequent side effects. Therefore, alternative treatments or combinations of treatments are needed. The Children's Hyperactivity and Autism Research Treatment Study (CHARTS) is a randomized clinical trial comparing the individual and combined effects of atomoxetine and parent training to treat hyperactivity, inattentiveness, and noncompliance in children with ASD. Design challenges included the overall study design, targeting of different outcomes by different treatments, and data analysis. This article details options for addressing a number of these methodological issues in the context of conducting a large multicenter RCT with an ASD population. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233

Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder / Luc LECAVALIER in Journal of Autism and Developmental Disorders, 48-4 (April 2018)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 48-4 (April 2018) . - p.980-987 Titre : Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Luc LECAVALIER, Auteur ; Xueliang PAN, Auteur ; Tristram SMITH, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Laura SILVERMAN, Auteur ; Rameshwari V. TUMULURU, Auteur ; Jill HOLLWAY, Auteur ; Michael G. AMAN, Auteur Article en page(s) : p.980-987 Langues : Anglais (eng) Mots-clés : Atomoxetine  Attention deficit hyperactivity disorder  Autism spectrum disorder  Parent stress  Parent training Index. décimale : PER Périodiques Résumé : We previously reported a 2 x 2 randomized clinical trial of atomoxetine (ATX) and parent training (PT) for attention deficit hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 children with autism spectrum disorder, ages 5-14 years. Children were randomized to one of four conditions: ATX alone, placebo alone, ATX + PT, or PT + placebo. Both ATX and PT improved some indices of ADHD and behavioral compliance. In this report, we describe parent stress over time and across conditions. All four treatments improved parent self-rated stress from baseline to week 10. However, there were no statistically significant differences between treatment groups. Significantly more improvement in parent stress scores was observed for clinical responders than non-responders. ClinicalTrials.gov Title: Atomoxetine, Placebo and Parent Management Training in Autism (Strattera) ClinicalTrials.gov Identifier: NCT00844753. En ligne : http://dx.doi.org/10.1007/s10803-017-3345-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=351 [article] Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder [texte imprimé] / Luc LECAVALIER, Auteur ; Xueliang PAN, Auteur ; Tristram SMITH, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Laura SILVERMAN, Auteur ; Rameshwari V. TUMULURU, Auteur ; Jill HOLLWAY, Auteur ; Michael G. AMAN, Auteur . - p.980-987. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 48-4 (April 2018) . - p.980-987 Mots-clés : Atomoxetine  Attention deficit hyperactivity disorder  Autism spectrum disorder  Parent stress  Parent training Index. décimale : PER Périodiques Résumé : We previously reported a 2 x 2 randomized clinical trial of atomoxetine (ATX) and parent training (PT) for attention deficit hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 children with autism spectrum disorder, ages 5-14 years. Children were randomized to one of four conditions: ATX alone, placebo alone, ATX + PT, or PT + placebo. Both ATX and PT improved some indices of ADHD and behavioral compliance. In this report, we describe parent stress over time and across conditions. All four treatments improved parent self-rated stress from baseline to week 10. However, there were no statistically significant differences between treatment groups. Significantly more improvement in parent stress scores was observed for clinical responders than non-responders. ClinicalTrials.gov Title: Atomoxetine, Placebo and Parent Management Training in Autism (Strattera) ClinicalTrials.gov Identifier: NCT00844753. En ligne : http://dx.doi.org/10.1007/s10803-017-3345-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=351

---

1 (1 - 3 / 3) Par page : 25 50 100 200